What is CJC-1295 DAC?

CJC-1295 DAC is a long-acting synthetic analogue of growth hormone-releasing hormone, often shortened to GHRH. The DAC part stands for Drug Affinity Complex, which allows the peptide to bind reversibly to albumin and remain active for longer than non-DAC GHRH analogues.

In research discussions, CJC-1295 DAC is usually associated with the growth hormone and IGF-1 axis. It is commonly discussed for sustained GH signalling, IGF-1 elevation, body composition research, recovery pathways and anabolic signalling.

CJC-1295 DAC Reconstitution Example

The example below is based on a common 5mg CJC-1295 DAC vial mixed with 2.0mL bacteriostatic water.

Standard / Gradual Research Protocol Example

This example uses a 5mg vial reconstituted with 2.0mL bacteriostatic water, giving an approximate concentration of 2,500mcg/mL.

Frequency and Timing Notes

CJC-1295 DAC is commonly discussed as a twice-weekly subcutaneous compound because the DAC modification extends its activity. Example schedules often use Monday and Thursday, or Tuesday and Friday, to keep injections spaced around 3-4 days apart.

Once-weekly use has also been studied, but many research-style protocols use twice-weekly timing for steadier exposure. The uploaded guide notes that the DAC modification may extend half-life to around 6-8 days, which is why CJC-1295 DAC is usually dosed less often than non-DAC GHRH analogues.

For very small measurements around 10 units or less, a 30-unit or 50-unit insulin syringe may be easier to read than a larger 1mL syringe.

Reconstitution Steps

1. Confirm the vial size before calculating concentration.
2. Draw 2.0mL bacteriostatic water using sterile technique.
3. Inject the bacteriostatic water slowly down the inside wall of the vial.
4. Avoid blasting the powder directly and avoid creating foam.
5. Gently swirl or roll the vial until the powder is fully dissolved.
6. Do not shake aggressively.
7. Label the vial with the reconstitution date.
8. Store the reconstituted vial in the refrigerator at 2-8°C, protected from light.

Supplies Needed

The following example is based on an 8-16 week twice-weekly research-style schedule using 5mg CJC-1295 DAC vials.

Protocol Overview

• Goal discussed in research: sustained GH and IGF-1 elevation for GH-axis research.
• Schedule example: twice-weekly subcutaneous use for 8-12 weeks, with some examples extending to 16 weeks.
• Example amount range: 300-1,000mcg per injection using gradual titration.
• Example reconstitution: 2.0mL bacteriostatic water per 5mg vial.
• Concentration: 2.5mg/mL, or 2,500mcg/mL.
• Spacing: injections commonly spaced 3-4 days apart.
• Storage: lyophilised vials stored frozen or cool as directed, reconstituted vials refrigerated.

Example Dosing Protocol

• Start: 300mcg per injection, twice weekly.
• Progression: increase by around 250mcg every 2 weeks as tolerated in research-style examples.
• Target example: 750-1,000mcg per injection by weeks 5-12.
• Frequency: twice weekly, spaced 3-4 days apart.
• Cycle length: 8-12 weeks, with optional extension to 16 weeks in some protocols.
• Timing: use a consistent schedule, often evening timing in example protocols.

How CJC-1295 DAC Works

CJC-1295 DAC mimics natural GHRH by binding to GHRH receptors on pituitary somatotrophs. This stimulates growth hormone release, which can then increase IGF-1 production, primarily in the liver.

The DAC modification is the key difference between CJC-1295 DAC and non-DAC versions. It helps the molecule stay active for days rather than minutes by binding to albumin.

Research also suggests that pulsatile growth hormone secretion can continue during CJC-1295 stimulation, meaning GH release patterns may not become completely flat or constant.

Potential Benefits Discussed in Research

• Sustained growth hormone signalling
• IGF-1 elevation in a dose-dependent manner
• Lean body mass research
• Body composition research
• Recovery and anabolic signalling
• Protein synthesis pathways
• GH-axis research models

Reported Side Effects and Limitations

CJC-1295 DAC is generally discussed as well tolerated in clinical research settings, but side effects can still occur, particularly during titration.

• Mild injection-site redness
• Swelling or irritation around the injection site
• Transient flushing
• Headache
• Water retention
• Possible changes related to GH and IGF-1 elevation
• Unknown long-term outcomes outside studied settings

Storage Instructions

• Lyophilised powder: store frozen or cool, dry and protected from light as directed by the supplier.
• After reconstitution: refrigerate at 2-8°C.
• Use window: commonly discussed as 2-4 weeks after reconstitution.
• Avoid: heat, sunlight, repeated freeze-thaw cycles and leaving the vial at room temperature for extended periods.
• Practical note: allow cold vials to reach room temperature before opening to reduce condensation exposure.

Injection Technique Notes

This section is general educational information only. It is not personal injection instruction.

• Use a new sterile insulin syringe for each administration.
• Clean the vial stopper and skin with alcohol and allow to dry.
• Common subcutaneous sites discussed include abdomen, thighs and upper arms.
• Rotate injection sites to reduce local irritation.
• Pinch a skinfold and insert into subcutaneous tissue at an appropriate angle.
• Do not aspirate for subcutaneous injections.
• Inject slowly and steadily.
• Wait a few seconds before withdrawing the needle.
• Do not rub or massage the injection site after administration.
• Dispose of used sharps safely in a sharps container.

Lifestyle Factors That May Matter

• Protein-forward diet: supports recovery and body composition goals.
• Resistance training: may complement GH-axis and lean mass research goals.
• Aerobic activity: supports general metabolic health.
• Sleep: quality sleep matters because natural GH release is strongly linked with deep sleep.
• Stress management: chronic stress can affect hormonal balance and consistency.
• Consistent timing: helps keep research protocols easier to follow and compare.

Use the Peptide Calculator

If your vial size, water volume or target amount is different, use the Peptide Hub Australia calculator to work out concentration, mL and syringe units.

Where to Compare CJC-1295 DAC Suppliers

Peptide Hub Australia does not sell CJC-1295 DAC or any other peptides. We compare Australian peptide vendors, package audits, pricing and supplier information to help users review the market more clearly.

Frequently Asked Questions

How much BAC water do you add to a 5mg CJC-1295 DAC vial?

A common educational example is 2.0mL bacteriostatic water added to a 5mg vial, creating a concentration of 2.5mg/mL, or 2,500mcg/mL.

How many units is 300mcg of CJC-1295 DAC?

If a 5mg vial is mixed with 2.0mL, 300mcg is approximately 12 units on a U-100 insulin syringe.

How many units is 500mcg of CJC-1295 DAC?

Using the same 5mg in 2.0mL example, 500mcg is approximately 20 units on a U-100 insulin syringe.

How many units is 1,000mcg of CJC-1295 DAC?

Using the same 5mg in 2.0mL example, 1,000mcg is approximately 40 units on a U-100 insulin syringe.

How often is CJC-1295 DAC discussed in research protocols?

CJC-1295 DAC is commonly discussed as a twice-weekly compound because of its longer activity profile, although once-weekly approaches have also been studied.

What is the difference between CJC-1295 DAC and non-DAC?

The DAC version binds to albumin and remains active much longer. Non-DAC versions are shorter acting and are usually discussed with different timing.

Is this a personal dosing recommendation?

No. This page is an educational reconstitution and measurement guide only. It is not medical advice or a personal protocol.

Related Resources

• Peptide Calculator
• Compare Australian Peptide Vendors
• Compare Peptide Prices
• Package Audits